Spots Global Cancer Trial Database for ros1
Every month we try and update this database with for ros1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | NCT02568267 | Breast Cancer Cholangiocarcin... Colorectal Canc... Head and Neck N... Lymphoma, Large... Melanoma Neuroendocrine ... Non-Small Cell ... Ovarian Cancer Pancreatic Canc... Papillary Thyro... Primary Brain T... Renal Cell Carc... Sarcomas Salivary Gland ... Adult Solid Tum... | Entrectinib | 18 Years - | Hoffmann-La Roche | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer | NCT06436885 | Non-Small Cell ... | Iruplinalkib ta... | 18 Years - | Henan Cancer Hospital | |
| Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations | NCT05845671 | Lung Cancer Non Small Cell ... | Amivantamab 105... Amivantamab 140... Amivantamab (to... Amivantamab (to... | 18 Years - 90 Years | University of Colorado, Denver | |
| A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | NCT06140836 | Carcinoma, Non-... | Repotrectinib Crizotinib | 18 Years - | Bristol-Myers Squibb | |
| A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer | NCT02034097 | Cancer | Foretinib Erlotinib | 18 Years - | GlaxoSmithKline | |
| Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) | NCT02186821 | Tumors With Abe... | Ceritinib | 18 Years - | Novartis | |
| PF-07284892 in Participants With Advanced Solid Tumors | NCT04800822 | Solid Tumor | PF-07284892 lorlatinib binimetinib cetuximab encorafenib | 18 Years - | Pfizer | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients | NCT02473497 | Neoplasm | Crizotinib | 0 Years - | Pfizer | |
| Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC | NCT01945021 | Non Small Cell ... ROS1 Proto Onco... Crizotinib | Crizotinib | 18 Years - | Pfizer | |
| EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer | NCT02183870 | Lung Cancer Adenocarcinoma NSCLC | Crizotinib | 18 Years - | University of Cologne | |
| REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis | NCT06315010 | NSCLC Brain Metastase... ROS1 Gene Rearr... | Repotrectinib | 18 Years - | MedSIR | |
| Study of Oral JYP0322 in Patients With Locally Advanced or Metastatic Cancer Targeting ROS1 Molecular Fusion. | NCT06128148 | Protein Kinase ... Other Protocol ... Lung Neoplasms Brain Neoplasms | JYP0322 | 18 Years - | Guangzhou JOYO Pharma Co., Ltd | |
| A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | NCT06140836 | Carcinoma, Non-... | Repotrectinib Crizotinib | 18 Years - | Bristol-Myers Squibb | |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | NCT02650401 | Solid Tumors CNS Tumors | Entrectinib | 0 Years - 18 Years | Hoffmann-La Roche | |
| Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC | NCT02824094 | Neoplasms Carcinoma, Non-... | crizotinib | 20 Years - | Pfizer | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer | NCT02183870 | Lung Cancer Adenocarcinoma NSCLC | Crizotinib | 18 Years - | University of Cologne | |
| Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC | NCT02824094 | Neoplasms Carcinoma, Non-... | crizotinib | 20 Years - | Pfizer | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| PF-07284892 in Participants With Advanced Solid Tumors | NCT04800822 | Solid Tumor | PF-07284892 lorlatinib binimetinib cetuximab encorafenib | 18 Years - | Pfizer | |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | NCT02650401 | Solid Tumors CNS Tumors | Entrectinib | 0 Years - 18 Years | Hoffmann-La Roche | |
| Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors | NCT02675491 | Advanced Solid ... | DS-6051b | 20 Years - | Daiichi Sankyo |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
